These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10631423)

  • 21. Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole.
    Orni-Wasserlauf R; Izkhakov E; Siegman-Igra Y; Bash E; Polacheck I; Giladi M
    Clin Infect Dis; 1999 Dec; 29(6):1592-3. PubMed ID: 10585832
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.
    Póvoa P; Gonçalves-Pereira J
    Crit Care; 2011; 15(1):114. PubMed ID: 21345263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute hepatitis and rash to fluconazole.
    Su FW; Perumalswami P; Grammer LC
    Allergy; 2003 Nov; 58(11):1215-6. PubMed ID: 14616149
    [No Abstract]   [Full Text] [Related]  

  • 24. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
    Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
    Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifungals in systemic neonatal candidiasis.
    Frattarelli DA; Reed MD; Giacoia GP; Aranda JV
    Drugs; 2004; 64(9):949-68. PubMed ID: 15101785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifungal prophylaxis in bone marrow transplant.
    Lam HH; Althaus BL
    Ann Pharmacother; 1995 Sep; 29(9):921-4. PubMed ID: 8547742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment.
    Linnebur SA; Parnes BL
    Ann Pharmacother; 2004 Apr; 38(4):612-6. PubMed ID: 14966256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary cutaneous cryptococcosis in transplant recipients: a report of two cases].
    Droitcourt C; Adamski H; Arvieux C; Chevrier S; Le Gall F; Michelet C; Chevrant-Breton J
    Rev Med Interne; 2005 Feb; 26(2):157-9. PubMed ID: 15710267
    [No Abstract]   [Full Text] [Related]  

  • 30. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
    Saag MS; Powderly WG; Cloud GA; Robinson P; Grieco MH; Sharkey PK; Thompson SE; Sugar AM; Tuazon CU; Fisher JF
    N Engl J Med; 1992 Jan; 326(2):83-9. PubMed ID: 1727236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryptococcal liver abscess: a case report of successful treatment with amphotericin-B and literature review.
    Liu PY; Yang Y; Shi ZY
    Jpn J Infect Dis; 2009 Jan; 62(1):59-60. PubMed ID: 19168962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Successful discontinuation of antifungal secondary prophylaxis in AIDS-related cryptococcosis].
    Negroni R; Helou SH; López Daneri G; Robles AM; Arechavala AI; Bianchi MH
    Rev Argent Microbiol; 2004; 36(3):113-7. PubMed ID: 15559192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
    Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
    BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible cardiomyopathy following treatment with amphotericin B and flucytosine.
    Johnson RE; Campbell-Bright S; Raasch RH; Rodgers JE; Rosenberg BS
    Int J Antimicrob Agents; 2008 Jun; 31(6):582-4. PubMed ID: 18456461
    [No Abstract]   [Full Text] [Related]  

  • 37. [Amphotericin B: the end of an era].
    Rommes JH; Spronk PE; Saene HK
    Ned Tijdschr Geneeskd; 2005 Jan; 149(2):106; author reply 106-7. PubMed ID: 15688845
    [No Abstract]   [Full Text] [Related]  

  • 38. Caspofungin: new indication. No progress in invasive candidiasis.
    Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
    Winston DJ; Schiller GJ
    Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.